NCT02057887View on ClinicalTrials.gov

Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2014

Conditions
Chronic Hepatitis C Virus Genotype I
Interventions
DRUG

HM10660A

DRUG

Pegasys

180 mcg Pegasys SC once weekly

Trial Locations (1)

Unknown

RECRUITING

Hanmi Clinical, Estado de México

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT02057887 - Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A) | Biotech Hunter | Biotech Hunter